{"prompt": "['2016N293064_03', 'CONFIDENTIAL', '2018N394263_00', '205864', 'For patients with underlying bundle branch block, follow the discontinuation criteria', 'listed below:', 'Baseline QTc with Bundle Branch Block', 'Discontinuation QTc with Bundle', 'Branch Block', '< 450 msec', '> 500 msec', '450 - 480 msec', '> 530 msec', 'See the SoA (Table 1) for data to be collected at the time of treatment discontinuation and', 'follow-up and for any further evaluations that need to be completed.', '8.1.3.', 'Neutrophil Stopping Criteria', 'A participant with a peripheral blood neutrophil count < 0.5 X 109/L that is confirmed on', 'repeat testing will be instructed to suspend dosing. The neutrophil count should be', 'monitored daily until it returns to within the baseline value, as detailed in Appendix 9.', '8.1.4.', 'Temporary Discontinuation', 'Temporary discontinuation of study treatment is allowed for up to 14 days when', 'medically necessary, e.g. for hospitalization for a COPD exacerbation, other medical', 'condition requiring hospitalization, or reduction in peripheral blood neutrophil counts', '0.5 X 109/L. Temporary discontinuation for any other reason should be discussed with', 'the GSK Medical Monitor.', '8.1.5.', 'Study Treatment Restart', 'Study treatment restart after liver chemistry stopping criteria are met by any participant in', 'this study is not allowed. Refer to Appendix 7 (Section 12.7) for full guidance for', 'required actions and follow-up assessments to undertake if liver stopping criteria are met.', 'Study treatment restart after neutrophil stopping criteria are met can be considered once', 'the neutrophil count has returned to within baseline and provided that no more than 14', 'days have elapsed since study medication was halted. The Investigator must obtain', 'approval from the GSK Medical Monitor prior to restarting study treatment. See', 'Appendix 9 for the procedure to be followed for study treatment restart after neutrophil', 'stopping criteria are met.', '8.2.', 'Withdrawal from the Study', 'A participant may withdraw from the study at any time at his/her own request,', 'or may be withdrawn at any time at the discretion of the investigator for safety,', 'behavioural, compliance or administrative reasons.', 'If the participant withdraws consent for disclosure of future information, the', 'sponsor may retain and continue to use any data collected before such a', 'withdrawal of consent.', '35']['2016N293064_03', 'CONFIDENTIAL', '2018N394263_00', '205864', 'If a participant withdraws from the study, he/she may request destruction of any', 'samples taken and not tested, and the investigator must document this in the site', 'study records.', 'Refer to the SoA for data to be collected at the time of study discontinuation and', 'follow-up and for any further evaluations that need to be completed.', '8.3.', 'Lost to Follow Up', 'A participant will be considered lost to follow-up if he or she repeatedly fails to return for', 'scheduled visits and is unable to be contacted by the study site.', 'The following actions must be taken if a participant fails to return to the clinic for a', 'required study visit:', 'The site must attempt to contact the participant and reschedule the missed visit', 'as soon as possible and counsel the participant on the importance of maintaining', 'the assigned visit schedule and ascertain whether or not the participant wishes to', 'and/or should continue in the study.', 'Before a participant is deemed lost to follow up, the investigator or designee', 'must make every effort to regain contact with the participant (where possible, 3', \"telephone calls and, if necessary, a certified letter to the participant's last known\", 'mailing address or local equivalent methods). These contact attempts should be', \"documented in the participant's medical record.\", 'Should the participant continue to be unreachable, he/she will be considered to', 'have withdrawn from the study with a primary reason of lost to follow-up.', '36']\n\n###\n\n", "completion": "END"}